TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
Brief Summary: The purpose of the study is to further evaluate the safety and efficacy of EUR-1008 as compared to Kreon® in the treatment of exocrine pancreatic insufficiency associated with Cystic Fibrosis in subjects 12 years of age and older.


Options:
A: Arm Label: EUR-1008 (APT-1008) First, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 (APT-1008), Drug: Placebo | Arm Label: Placebo First, Then EUR-1008 (APT-1008); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008)
B: Arm Label: EUR-1008 then Kreon; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 25,000 Units, Drug: Kreon 25,000 Units | Arm Label: Kreon then EUR-1008; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 25,000 Units, Drug: Kreon 25,000 Units | Intervention Type: DRUG; Name: EUR-1008 25,000 Units; Assigned to Arm(s): EUR-1008 then Kreon, Kreon then EUR-1008 | Intervention Type: DRUG; Name: Kreon 25,000 Units; Assigned to Arm(s): EUR-1008 then Kreon, Kreon then EUR-1008
C: Arm Label: Burlulipase; Type: EXPERIMENTAL; Interventions: Drug: Burlulipase | Arm Label: Placebo (Caramel in sterile water); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Caramel in sterile water) | Intervention Type: DRUG; Name: Burlulipase; Assigned to Arm(s): Burlulipase | Intervention Type: DRUG; Name: Placebo (Caramel in sterile water); Assigned to Arm(s): Placebo (Caramel in sterile water)
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pancrelipase Delayed Release | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Pancrelipase Delayed Release; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
Brief Summary: The purpose of the study is to further evaluate the safety and efficacy of EUR-1008 as compared to Kreon® in the treatment of exocrine pancreatic insufficiency associated with Cystic Fibrosis in subjects 12 years of age and older.


Options:
A: Arm Label: EUR-1008 then Kreon; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 25,000 Units, Drug: Kreon 25,000 Units | Arm Label: Kreon then EUR-1008; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 25,000 Units, Drug: Kreon 25,000 Units | Intervention Type: DRUG; Name: EUR-1008 25,000 Units; Assigned to Arm(s): EUR-1008 then Kreon, Kreon then EUR-1008 | Intervention Type: DRUG; Name: Kreon 25,000 Units; Assigned to Arm(s): EUR-1008 then Kreon, Kreon then EUR-1008
B: Arm Label: Cystic Fibrosis in 1st 3 months of life; Type: N/A; Interventions: N/A
C: Arm Label: Burlulipase; Type: EXPERIMENTAL; Interventions: Drug: Burlulipase | Arm Label: Placebo (Caramel in sterile water); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Caramel in sterile water) | Intervention Type: DRUG; Name: Burlulipase; Assigned to Arm(s): Burlulipase | Intervention Type: DRUG; Name: Placebo (Caramel in sterile water); Assigned to Arm(s): Placebo (Caramel in sterile water)
D: Arm Label: Patients with CF; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Arm Label: Age-matched healthy controls; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Intervention Type: DIAGNOSTIC_TEST; Name: Questionnaire Patient Reported Outcome Measure (PROM); Assigned to Arm(s): Age-matched healthy controls, Patients with CF

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
Brief Summary: The purpose of the study is to further evaluate the safety and efficacy of EUR-1008 as compared to Kreon® in the treatment of exocrine pancreatic insufficiency associated with Cystic Fibrosis in subjects 12 years of age and older.


Options:
A: Arm Label: EUR-1008 then Kreon; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 25,000 Units, Drug: Kreon 25,000 Units | Arm Label: Kreon then EUR-1008; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 25,000 Units, Drug: Kreon 25,000 Units | Intervention Type: DRUG; Name: EUR-1008 25,000 Units; Assigned to Arm(s): EUR-1008 then Kreon, Kreon then EUR-1008 | Intervention Type: DRUG; Name: Kreon 25,000 Units; Assigned to Arm(s): EUR-1008 then Kreon, Kreon then EUR-1008
B: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
C: Arm Label: GLP-1 Incretin Hormone; Type: EXPERIMENTAL; Interventions: Drug: GLP-1 | Arm Label: GIP Incretin Hormone; Type: EXPERIMENTAL; Interventions: Drug: GIP | Intervention Type: DRUG; Name: GLP-1; Assigned to Arm(s): GLP-1 Incretin Hormone | Intervention Type: DRUG; Name: GIP; Assigned to Arm(s): GIP Incretin Hormone
D: Arm Label: EUR-1008 (APT-1008) First, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 (APT-1008), Drug: Placebo | Arm Label: Placebo First, Then EUR-1008 (APT-1008); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas Aeruginosa Infection in Subjects With Cystic Fibrosis
Brief Summary: The primary objective of this study is to evaluate the safety and efficacy of a CAT regimen with aztreonam for inhalation solution (AZLI) and tobramycin inhalation solution (TIS) in adult and pediatric subjects with cystic fibrosis (CF) and pulmonary Pseudomonas aeruginosa (PA) infection. Participants will be enrolled in a 28 day TIS run-in phase, and will be eligible for randomization in the comparative phase if they have not received non-study oral antibiotics for a respiratory event, or IV or inhaled antibiotics for any indication between Visits 2 and 3, have not developed a condition requiring hospitalization or other change in clinical status which, in the opinion of the investigator would preclude their ability to continue in the study, and have demonstrated at least 50% TIS compliance. Participants enrolled in the comparative phase will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: AZLI or placebo for 28 days followed by TIS for 28 days.


Options:
A: Arm Label: AZLI; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZLI, Drug: Tobramycin inhalation solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match AZLI, Drug: Tobramycin inhalation solution | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI | Intervention Type: DRUG; Name: Placebo to match AZLI; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tobramycin inhalation solution; Assigned to Arm(s): AZLI, Placebo
B: Arm Label: Aeroquin; Type: EXPERIMENTAL; Interventions: Drug: MP-376 (Levofloxacin Solution for Inhalation) | Arm Label: TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIS (Tobramycin Inhalation Solution) | Intervention Type: DRUG; Name: MP-376 (Levofloxacin Solution for Inhalation); Assigned to Arm(s): Aeroquin | Intervention Type: DRUG; Name: TIS (Tobramycin Inhalation Solution); Assigned to Arm(s): TIS
C: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days
D: Arm Label: Observational; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Brief Summary: The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.


Options:
A: Arm Label: Pemetrexed/Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Bevacizumab | Arm Label: Pemetrexed/Bevacizumab/Carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Bevacizumab, Drug: Carboplatin | Arm Label: Pemetrexed; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed, Pemetrexed/Bevacizumab, Pemetrexed/Bevacizumab/Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Pemetrexed/Bevacizumab, Pemetrexed/Bevacizumab/Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pemetrexed/Bevacizumab/Carboplatin
B: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel
C: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: pembrolizumab | Intervention Type: DRUG; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Brief Summary: The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.


Options:
A: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel
B: Arm Label: Nivolumab monotherapy (Dose Escalation); Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Nivolumab + Lirilumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Lirilumab | Arm Label: Nivo + Dara + Pom + Dexa vs. Nivo + Dara; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Daratumumab, Drug: Pomalidomide, Drug: Dexamethasone | Arm Label: Daratumumab vs. Nivolumab + Daratumumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Daratumumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Daratumumab vs. Nivolumab + Daratumumab, Nivo + Dara + Pom + Dexa vs. Nivo + Dara, Nivolumab + Ipilimumab, Nivolumab + Lirilumab, Nivolumab monotherapy (Dose Escalation) | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: BIOLOGICAL; Name: Lirilumab; Assigned to Arm(s): Nivolumab + Lirilumab | Intervention Type: BIOLOGICAL; Name: Daratumumab; Assigned to Arm(s): Daratumumab vs. Nivolumab + Daratumumab, Nivo + Dara + Pom + Dexa vs. Nivo + Dara | Intervention Type: DRUG; Name: Pomalidomide; Assigned to Arm(s): Nivo + Dara + Pom + Dexa vs. Nivo + Dara | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Nivo + Dara + Pom + Dexa vs. Nivo + Dara
C: Arm Label: Brentuximab vedotin; Type: EXPERIMENTAL; Interventions: Drug: brentuximab vedotin | Intervention Type: DRUG; Name: brentuximab vedotin; Assigned to Arm(s): Brentuximab vedotin
D: Arm Label: Nivolumab (Cohort A, B, C and D); Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Doxorubicin, Drug: Vinblastine, Drug: Dacarbazine | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab (Cohort A, B, C and D) | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Nivolumab (Cohort A, B, C and D) | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Nivolumab (Cohort A, B, C and D) | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Nivolumab (Cohort A, B, C and D)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Brief Summary: The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.


Options:
A: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel
B: Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II
C: Arm Label: ARM 1 CRT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin | Arm Label: ARM 2 PRT; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): ARM 2 PRT | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): ARM 1 CRT
D: Arm Label: Panitumumab Plus Chemoradiation; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Radiation: Standard Fractionation Radiotherapy, Drug: Panitumumab | Arm Label: Chemoradiotherapy Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Radiation: Standard Fractionation Radiotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Chemoradiotherapy Alone, Panitumumab Plus Chemoradiation | Intervention Type: RADIATION; Name: Standard Fractionation Radiotherapy; Assigned to Arm(s): Chemoradiotherapy Alone, Panitumumab Plus Chemoradiation | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab Plus Chemoradiation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension
Brief Summary: This is a clinical trial to test an experimental drug for the treatment of Eosinophilic Esophagitis (EoE)


Options:
A: Arm Label: inhaled/swallowed budesonide; Type: EXPERIMENTAL; Interventions: Drug: inhaled/swallowed budesonide | Arm Label: viscous/swallowed budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: viscous/swallowed budesonide | Intervention Type: DRUG; Name: inhaled/swallowed budesonide; Assigned to Arm(s): inhaled/swallowed budesonide | Intervention Type: DRUG; Name: viscous/swallowed budesonide; Assigned to Arm(s): viscous/swallowed budesonide
B: Arm Label: Part A: Dupilumab or Placebo; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Part B: Dupilumab or Placebo; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Part C: Dupilumab; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Part A: Dupilumab or Placebo, Part B: Dupilumab or Placebo, Part C: Dupilumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part A: Dupilumab or Placebo, Part B: Dupilumab or Placebo
C: Arm Label: Oral Budesonide Suspension; Type: EXPERIMENTAL; Interventions: Drug: Oral Budesonide Suspension (MB-9) | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral Budesonide Suspension (MB-9); Assigned to Arm(s): Oral Budesonide Suspension | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching Placebo
D: Intervention Type: DRUG; Name: mepolizumab; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinic, Family & Community Collaboration to Treat Overweight and Obese Children
Brief Summary: Stanford GOALS is a large-scale, community-based randomized controlled trial of an innovative, interdisciplinary, multi-component, multi-level, multi-setting (MMM) approach to treating overweight and obese children. Primary Research Question: Will a 3-year, innovative, interdisciplinary, multi-component, multi-level, multi-setting (MMM) community-based intervention to treat overweight and obese children significantly reduce BMI compared to an enhanced standard care/health and nutrition education active comparison intervention?


Options:
A: Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity | Arm Label: Wait List Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Physical Activity | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Treatment Group, Wait List Group
B: Arm Label: multi-component, multi-level, multi-setting (MMM); Type: EXPERIMENTAL; Interventions: Behavioral: MMM | Arm Label: Health and Nutrition Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health and Nutrition Education | Intervention Type: BEHAVIORAL; Name: MMM; Assigned to Arm(s): multi-component, multi-level, multi-setting (MMM) | Intervention Type: BEHAVIORAL; Name: Health and Nutrition Education; Assigned to Arm(s): Health and Nutrition Education
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: A 5-months physical exercise-based program | Intervention Type: BEHAVIORAL; Name: A 5-months physical exercise-based program; Assigned to Arm(s): Intervention Group
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: placebo | Arm Label: lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: multimodal lifestyle intervention | Intervention Type: BEHAVIORAL; Name: multimodal lifestyle intervention; Assigned to Arm(s): lifestyle intervention | Intervention Type: BEHAVIORAL; Name: placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinic, Family & Community Collaboration to Treat Overweight and Obese Children
Brief Summary: Stanford GOALS is a large-scale, community-based randomized controlled trial of an innovative, interdisciplinary, multi-component, multi-level, multi-setting (MMM) approach to treating overweight and obese children. Primary Research Question: Will a 3-year, innovative, interdisciplinary, multi-component, multi-level, multi-setting (MMM) community-based intervention to treat overweight and obese children significantly reduce BMI compared to an enhanced standard care/health and nutrition education active comparison intervention?


Options:
A: Intervention Type: BEHAVIORAL; Name: Switch active lifestyles brought to you by MediaWise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Switch active lifestyles from MediaWise; Assigned to Arm(s): N/A
B: Arm Label: Intervention camp; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention camp | Arm Label: Small intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Small intervention | Intervention Type: BEHAVIORAL; Name: Small intervention; Assigned to Arm(s): Small intervention | Intervention Type: BEHAVIORAL; Name: Intervention camp; Assigned to Arm(s): Intervention camp
C: Arm Label: multi-component, multi-level, multi-setting (MMM); Type: EXPERIMENTAL; Interventions: Behavioral: MMM | Arm Label: Health and Nutrition Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health and Nutrition Education | Intervention Type: BEHAVIORAL; Name: MMM; Assigned to Arm(s): multi-component, multi-level, multi-setting (MMM) | Intervention Type: BEHAVIORAL; Name: Health and Nutrition Education; Assigned to Arm(s): Health and Nutrition Education
D: Arm Label: Breakfast Skipping; Type: EXPERIMENTAL; Interventions: Behavioral: Breakfast Skipping | Arm Label: Normal Protein Breakfast Meals; Type: EXPERIMENTAL; Interventions: Behavioral: Normal Protein Breakfast Meals | Arm Label: Protein-rich Breakfast Meals; Type: EXPERIMENTAL; Interventions: Behavioral: Protein-rich Breakfast Meals | Intervention Type: BEHAVIORAL; Name: Breakfast Skipping; Assigned to Arm(s): Breakfast Skipping | Intervention Type: BEHAVIORAL; Name: Normal Protein Breakfast Meals; Assigned to Arm(s): Normal Protein Breakfast Meals | Intervention Type: BEHAVIORAL; Name: Protein-rich Breakfast Meals; Assigned to Arm(s): Protein-rich Breakfast Meals

Answer: C